The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans

Nathan P. Wiederhold, Laura K. Najvar, Annette W. Fothergill, Rosie Bocanegra, Marcos Olivo, Dora I. McCarthy, William R. Kirkpatrick, Yoshiko Fukuda, Junichi Mitsuyama, Thomas F. Pattersona

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.

Original languageEnglish (US)
Pages (from-to)1341-1343
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume59
Issue number2
DOIs
StatePublished - Feb 1 2015

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans'. Together they form a unique fingerprint.

Cite this